Revascularization in severe left ventricular dysfunction: Outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting

Catheterization and Cardiovascular Interventions

Volumn 70, Issue 1, 2007, Pages 26-33

  Gioia, Giuseppe ^a   Matthai, William ^b   Gillin, Karen ^a   Dralle, James ^a   Benassi, Alberto ^c   Gioia, Maria Francesca ^a   White, Jacqueline ^a  

^a AtlantiCare Regional Medical Center Atlantic City Campus   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HESPERIA HOSPITAL   (Italy)

Author keywords

Coronary artery by pass grafting; Drug eluting stent; Left ventricular dysfunction

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CAUSE OF DEATH; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DISEASE SEVERITY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT CODING; PROBABILITY; STROKE; SURVIVAL RATE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PACLITAXEL; PROSTHESIS DESIGN; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SIROLIMUS; STENTS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34447121351     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21072     Document Type: Article

References (24)

1. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, Paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
3. Morice MC, Serruys PW, Sousa JE, et al., for the RAVEL study group. A randomized comparison of a Sirolimus-eluting stent with standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
4. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of Sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-195.
5. Medina A, Suarez de Lezo J, Pan M, et al. Sirolimus-eluting stents for treatment of in-stent restenosis: Immediate and late results. Tex Heart Inst J 2005;32:11-15.
6. Kastrati A, Mehilli J, von Beckerath N, et al. for the ISAR-DESIRE Study investigators. Sirolimus-eluting stent for Paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. JAMA 2005;293:165-171.
7. Serruys PW, et al. Arterial revascularization therapies study. II. Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions (ARTS II). Paper presented at the 2005 ACC 54th annual Scientific Session, Orlando, FL, March; 2005.
8. Holmes DR, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of Sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-640.
9. Moussa I, Leon MB, Baim D, et al. Impact of Sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (Sirolimus-coated Bx velocity balloon expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-2278.
10. Dangas G, Ellis SG, Shlofmitz R, et al. Outcomes of Paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. J Am Coll Cardiol 2005;45:1886-1892.
11. Gupta N, Debsikdar J, Brodie BR, et al. Drug-eluting stents vs. bare metal stents in patients with non-ST elevation myocardial infarction: Results from the STENT registry. Am J Cardiol 2004;94 (Suppl. 6):11E. Abstract TCT-25.
12. Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005;111:791-795.
13. Schofer J, Schluter M, Gerschlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.
14. Gioia G, Matthai W, Rana H, et al. Outcomes of drug-eluting stent implantation compared to bare metal stent in patients with severe left ventricular dysfunction. Cathet Cardiovasc Interv 2006;67:775.
15. Weyman AE. Appendix A: Normal cross-sectional echocardiographic measurements. In: Weyman AE, editor. Principles and Practice of Echocardiography. Philadelphia: Lea & Febiger; 1994.
16. Pfister ME, Kaiser CA, Bader F, et al. Late clinical events related to late stent thrombosis after stopping clopidogrel: Prospective randomized comparison between drug-eluting versus bare metal stent (BASKET-LATE trial). In: ACC 55th Annual Scientific Session, Barcelona, Spain, March 2006. Abstract no. 422-11.
17. Moss AJ, Zareba W, Hall WJ, et al., for the Multicenter Automatic Defibrillator Implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883.
18. Sedlis SP, Ramanathan KB, Morrison DA, Sethi G, Henderson W. Outcome of percutaneous coronary intervention versus coronary by-pass grafting for patients with low left ventricular ejection fraction, unstable angina pectoris, and risk factors for adverse outcome with by-pass (the AWESOME randomized trial and registry). Am J Cardiol 2004;94:118-120.
19. O'Keefe JH, Allan JJ, McCallister BD, et al. Angioplasty versus bypass surgery for multivessel coronary artery disease with left ventricular ejection fraction < than 40%. Am J Cardiol 1993;71:897-901.
20. Toda K, McKenzie K, Mehra MR, et al. Revascularization in severe ventricular dysfunction (15%< or =30%): A comparison of bypass grafting and percutaneous intervention. Ann Thorac Surg 2002;74:2082-2087.
21. Alderman E, Fisher LD, Litwin P, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 1983;68:785-795.
22. Bounous EP, Mark DB, Pollock BG, et al. Surgical survival benefits for coronary disease patients with left ventricular dysfunction. Circulation 1988;78:I151-I157.
23. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure: The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 1994;272:1528-1534.
24. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225.